Data on the prevalence of CKD among U.S. adults with T2D and CVD are limited.
The aim of this study was to provide such estimates for T2D, both overall and in those with CVD. Using the NHANES 2007-2014 data, we conducted a cross-sectional analysis of an adult sample with diagnosed and undiagnosed T2D (n=3271), aged ≥18 years. Appropriate sample weights were used to obtain a national estimate.
Results of prevalence of CKD in U.S. adults with T2D are presented in Table 1. The prevalence of moderately to severely decreased renal impairment based on eGFR < 60 ml/min/1.73m2 (Stage 3-5) was 18.0%. The prevalence of mildly decreased renal impairment (Stage 2, eGFR=60-90 ml/min/1.73m2) was 36.9%, including 28.3% with UACR<30 mg/g, 7.0% with UACR ≥ 30-300 mg/g and 1.6% with UACR>300mg/g.
For T2D and CVD subgroup (n=837), the prevalence of moderately to severely decreased renal impairment was 33.6% (Stage 3a: 16.1%; Stage 3b: 12.3%; Stage 4 or 5: 5.2%). The prevalence of mildly decreased renal impairment (Stage 2) was 42.8%, including 29.0% with UACR<30 mg/g, 11.8% with UACR≥ 30-300 mg/g and 2.1% with UACR >300mg/g.
This study confirms the high prevalence of CKD in patients with multiple comorbidities: T2D and CVD. It also provides insights into prevalence of all CKD categories based on KDIGO 2012 classification for U.S. adults with T2D, both overall and those with CVD.
T. Wang: Employee; Self; Merck & Co., Inc.. Stock/Shareholder; Self; Merck & Co., Inc.. Employee; Spouse/Partner; Janssen Pharmaceuticals, Inc.. Y. Xi: None. R.N. Lubwama: None. C. Koro: Employee; Self; Merck & Co., Inc.. Stock/Shareholder; Self; GlaxoSmithKline plc..